{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:04:31Z","timestamp":1781787871947,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijrobp.2025.11.042","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T15:58:38Z","timestamp":1764431918000},"page":"530-542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Stereotactic Body Radiation Therapy Augmented Checkpoint Inhibitor Immunotherapy Response in Heavily Pretreated Metastatic Osteosarcoma"],"prefix":"10.1016","volume":"125","author":[{"given":"Chuanying","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxiang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhusheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beichen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuochao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mawei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3508-9773","authenticated-orcid":false,"given":"Qiyuan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.11.042_bib0001","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/cncr.34163","article-title":"Osteosarcoma: A surveillance, epidemiology, and end results program-based analysis from 1975 to 2017","volume":"128","author":"Cole","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0002","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1302\/0301-620X.89B9.19255","article-title":"Twentieth-century survival from osteosarcoma in childhood","volume":"89-B","author":"Foster","year":"2007","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0003","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2018.11.027","article-title":"Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort","volume":"109","author":"Smeland","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0004","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra2103423","article-title":"New horizons in the treatment of osteosarcoma","volume":"385","author":"Meltzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0005","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: Systematic review and consensus recommendations by the EORTC\u2013ESTRO oligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0006","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/cac2.12226","article-title":"Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: Challenges and updates","volume":"41","author":"Shang","year":"2021","journal-title":"Cancer Commun"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0007","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0008","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3390\/cells9040976","article-title":"The osteosarcoma microenvironment: A complex but targetable ecosystem","volume":"9","author":"Corre","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0009","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.3390\/ijms23073817","article-title":"Recent and ongoing research into metastatic osteosarcoma treatments","volume":"23","author":"Harris","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.lungcan.2015.10.016","article-title":"Stereotactic body radiotherapy for early stage lung cancer: History and updated role","volume":"90","author":"Ricardi","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0011","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/360214","article-title":"Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma","volume":"2013","author":"Mehta","year":"2013","journal-title":"Sarcoma"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102206","article-title":"Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus","volume":"98","author":"Jereczek-Fossa","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0014","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.eururo.2022.06.017","article-title":"The role of stereotactic ablative body radiotherapy in renal cell carcinoma","volume":"82","author":"Ali","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0015","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.3390\/cancers13143623","article-title":"Stereotactic body radiotherapy for patients with lung oligometastatic disease: A five-year systematic review","volume":"13","author":"Virbel","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0016","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1158\/1078-0432.CCR-19-2034","article-title":"Radiotherapy and immunotherapy for cancer: From \u201cSystemic\u201d to \u201cMultisite","volume":"26","author":"Arina","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0017","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1158\/1078-0432.CCR-18-2581","article-title":"The reciprocity between radiotherapy and cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0018","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0019","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/COC.0000000000001000","article-title":"Stereotactic body radiation therapy for sarcoma pulmonary metastases","volume":"46","author":"Asha","year":"2023","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0020","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.3390\/cancers13194775","article-title":"Radiation therapy in metastatic soft tissue sarcoma: From palliation to ablation","volume":"13","author":"Shah","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0021","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0022","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Published: November 27, 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0023","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0024","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.3390\/cancers13174409","article-title":"Automated PD-L1 scoring using artificial intelligence in head and neck squamous cell carcinoma","volume":"13","author":"Puladi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0025","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3389\/fonc.2020.01198","article-title":"Immune landscape of the tumor microenvironment identifies prognostic gene signature CD4\/CD68\/CSF1R in osteosarcoma","volume":"10","author":"jiang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0026","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1737385","article-title":"Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: Relation to clinical outcome and Th1 pathway activation","volume":"9","author":"Wunder","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0027","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41467-020-14646-w","article-title":"Immuno-genomic landscape of osteosarcoma","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0028","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/418270","article-title":"Stereotactic body radiotherapy for metastatic and recurrent ewing sarcoma and osteosarcoma","volume":"2014","author":"Brown","year":"2014","journal-title":"Sarcoma"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103685","article-title":"SELNET clinical practice guidelines for bone sarcoma","volume":"174","author":"Blay","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2025.11.042_bib0031","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/pbc.21451","article-title":"Multimodality treatment of osteosarcoma: Radiation in a high-risk cohort","volume":"50","author":"Mahajan","year":"2008","journal-title":"Pediatr Blood Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625065216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625065216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:17:46Z","timestamp":1780388266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625065216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0360301625065216"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.11.042","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Body Radiation Therapy Augmented Checkpoint Inhibitor Immunotherapy Response in Heavily Pretreated Metastatic Osteosarcoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.11.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}